Physician profile
Rachel Harris
NPI 1700379799
$1,748.53
in general payments reported to CMS, 2019-2025
14 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $846 · 2022: $441 · 2023: $40.24 · 2024: $257 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $788.23 | 2021-2022 | |
| Polynovo North America LLC | $162.22 | 2022-2025 | Novosorb Btm |
| Tactile Systems Technology INC | $158.84 | 2022-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Abbott Laboratories | $146.31 | 2024 | Proclaim |
| Takeda Pharmaceuticals U.S.A., INC. | $124.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.62 | 2021 | |
| Mentor Worldwide LLC | $67.76 | 2024-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander |
| Dexcom, INC. | $53.80 | 2024 | Dexcom G6 Transmitter |
| Axogen | $25.89 | 2025 | |
| Janssen Biotech, INC. | $24.56 | 2025 | Talvey |
| Merck Sharp & Dohme LLC | $22.77 | 2025 | Keytruda |
| Kci USA, INC. | $19.65 | 2023 | V.A.C. Veraflo, V.A.C. Dermatac |
| Aroa Biosurgery Incorporated | $15.59 | 2025 | |
| Baxter Healthcare | $13.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.